Eli Lilly and Co
Why Eli Lilly’s earnings are no sure thing for traders despite obesity drug momentum
Eli Lilly appears to be making as much of its popular obesity and diabetes medicines as it can, but shortages are worsening , putting the company’s earnings at risk, analysts say. Tirzepatide is the active ingredient in both Eli Lilly’s diabetes treatment Mounjaro and its anti-obesity drug Zepbound. The Food and Drug Administration recently reported […]
Read More
Most people on weight loss drugs are spending less on restaurants and takeout, survey says
A food delivery messenger carries a take out bag outside aSweetgreen in Manhattan on September 14, 2023. Jeenah Moon | The Washington Post | Getty Images A highly popular group of weight loss and diabetes drugs is decreasing some consumers’ appetites — and also how much they spend on food. Most people taking those medications, […]
Read More
Promise of Eli Lilly’s weight-loss drug for sleep apnea adds another reason to own the stock
Eli Lilly ‘s weight-loss drug Zepbound showed promise as a treatment for sleep apnea — giving investors more confidence to keep owning the world’s most valuable health-care company even after it’s been crushing the S & P 500’s performance over the past three years. The study results released by Eli Lilly on Wednesday highlight the […]
Read More
Stocks building the largest moves midday: United Airlines, Travelers, Abbott Laboratories and a lot more
Check out out the companies producing headlines in midday buying and selling. United Airways — Shares surged 14% right after the airline posted a narrower-than-expected reduction in the very first quarter. Quarterly profits arrived in at $12.54 billion, topping an LSEG estimate of $12.45 billion. Tourists Companies — The insurance policies stock fell 8% just […]
Read More
Most doses of Eli Lilly’s Zepbound, Mounjaro in short supply through June, FDA says
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan McDermid | Reuters Most doses of Eli Lilly‘s highly popular weight loss drug Zepbound and diabetes counterpart Mounjaro will be in short supply through the second quarter of this year as demand jumps, according […]
Read More
Stocks producing the biggest premarket moves: Eli Lilly, Vacationers, United Airways, Alcoa and additional
Verify out the corporations producing the largest moves in premarket buying and selling: Eli Lilly , ResMed — Eli Lilly’s inventory moved 2% increased following the pharmaceutical giant’s announcement that its body weight loss drug Zepbound showed the probable to handle individuals with obstructive snooze apnea. Shares of ResMed, which makes devices to deal with […]
Read More
Eli Lilly’s weight loss drug Zepbound shows promise as a sleep apnea treatment in late-stage trials
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan McDermid | Reuters Eli Lilly on Wednesday said its highly popular weight loss drug Zepbound showed the potential to treat patients with the most common sleep-related breathing disorder in two late-stage clinical trials. The […]
Read More
EU probe of weight loss and diabetes drugs like Wegovy, Ozempic finds no link to suicidal thoughts
Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters European Union drug regulators found no evidence that highly popular weight loss and diabetes drugs such as Wegovy and Ozempic are linked to an increased risk of suicidal thoughts and self-injury, the regulator […]
Read More
Diabetes drug similar to Ozempic helped slow progression of Parkinson's disease in small trial
The coronal view of a human brain of a patient suffering from Parkinson’s disease Sherbrooke Connectivity Imaging Lab | Getty Images A highly popular class of drugs for diabetes and obesity is showing early potential to help patients with Parkinson’s disease, too. An older diabetes treatment called lixisenatide helped slow the progression of motor disability […]
Read More
Healthy Returns: Weight loss, diabetes drug ad spending tops $1 billion
Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! Drugmakers spent big on advertisements for weight loss and diabetes treatments last year […]
Read More